ArticleWorld journal of gastroenterology2025
Risk assessment of type I gastric neuroendocrine tumors based on endoscopic and clinical features of autoimmune gastritis.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From pre-tumor to tumor: Decoding the endoscopic-pathologic spectrum of neoplastic lesions in autoimmune gastritis.iScience · 2026Article
- Autoimmune gastritis: a comprehensive review of pathophysiology, risk stratification, and management.Frontiers in immunology · 2026Review
- Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort.Frontiers in endocrinology · 2026Article
- Unmasking the high-risk phenotype in autoimmune gastritis: A pathologist's roadmap for the clinician.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune gastritis (AIG) is frequently associated with one or more comorbid conditions, among which type I gastric neuroendocrine tumors (gNETs) warrant significant clinical concern. However, risk factors for the development of gNETs in AIG populations remain poorly defined.
aimTo characterize the clinical and endoscopic profiles of AIG and identify potential risk factors for gNETs development.
methodsIn this single-center cross-sectional study carried out at a tertiary hospital, 303 patients with AIG over an 8-year period were retrospectively categorized into gNETs (
resultsAmong the 303 patients with AIG, 116 had gNETs and 187 did not. Compared with the non-gNETs group, patients in the gNETs group were younger (54.3 years
conclusionPatients with AIG or gNETs exhibit specific clinical and endoscopic features. The predictive model demonstrated favorable discriminative ability and may facilitate risk stratification of gNETs in patients with AIG.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.